Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case of meningioma in a transwoman treated long-term with estradiol and cyproterone acetate, suggesting possible concern over female sex steroids and meningioma risk.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This review discusses hormonal influences and treatment considerations in female acne, particularly highlighting the role of androgens in persistent or resistant cases, and reports no new clinical findings.

This study observed that most hirsute patients on combined cyproterone acetate and 'Diane' therapy experienced a reduction in hair growth, with hair becoming softer, thinner, and lighter in color over 12 months.

This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.

This study found that combined treatment with anastrozole and cyproterone acetate improved the adult height prognosis in testotoxicosis, as observed in two brothers, with good tolerance reported.

In this study, women treated for androgen-dependent alopecia with CPA EE2 therapy experienced significant decreases in serum vitamin B12, hemoglobin, and hematocrit levels after six months.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

This study found that high-dose cyproterone acetate was effective for treating hirsutism, but 33% of patients felt their condition worsened on low-dose maintenance therapy, despite no significant change in objective measures of hair growth.

In this study, Diane was reported to effectively treat acne, seborrhoea, androgenic alopecia, and mild hirsutism in hirsute women, with its effectiveness influenced by the severity and duration of the condition.

This study observed a potential association between the CC genotype of rs4646 and female pattern hair loss, but the authors advise caution due to lack of experiment-wide significance and recommend replication.

This study found that testosterone propionate increased hair mass in female hamsters' flank organs, while cyproterone acetate applied topically reduced androgen-stimulated hair in a dose-dependent manner.

This study found that in patients with nonclassical 21-hydroxylase deficiency, genotypes do not reliably predict the severity of hyperandrogenic symptoms, suggesting other genetic factors may influence the phenotype.

This study found that both cyproterone acetate alone and combined with ethinyl oestradiol reduced androgen levels and slightly increased SHBG binding in women with hirsutism, but showed no difference in hair regrowth rate between the treatments.

In this study, oral cyproterone acetate reduced hair density and diameter in women with idiopathic hirsutism, but the effects were not permanent after stopping treatment, and plasma androgen levels remained unchanged.

This study found that regio-specific hydroxylation of cyclosporine A in Sebekia benihana is mediated by the cytochrome P450 hydroxylase CYP-sb21, suggesting potential biotechnological applications for hair growth promotion without immunosuppressive effects.

This study found that Cyperus rotundus essential oil is as effective as the Alexandrite laser in reducing the growth of unwanted axillary hair, with notable effectiveness in decreasing white hair growth.

This study reported that structure-guided engineering of CYP154C2 mutants significantly improved the 2α-hydroxylation of androstenedione and testosterone, with enhanced conversion efficiency and substrate selectivity compared to the wild-type enzyme.

This review discusses the historical and potential medical uses of Cyperus rotundus rhizomes, but reports no new clinical results and emphasizes the need for further study on its pharmacognostic properties.

This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics.

This report introduces a mouse model with androgen-dependent alopecia, suggesting it as a potential alternative for studying hair loss mechanisms and testing treatments.

This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.

This study observed that Cyp27b1−/− mice exhibited growth and skeletal abnormalities similar to those of Vdr−/− mice, despite differences like the development of alopecia in Vdr−/− mice, suggesting that 1α,25D3 may directly influence chondrocyte proliferation and differentiation.

This study found that specific genetic variants in the CYP21A2 and CYP19A1 genes were associated with severe acne vulgaris among Han Chinese, particularly in male patients.

This case study reports a 66-year-old woman developing shortness of breath while taking 50 mg/day of cyproterone acetate for androgenetic alopecia, a complication not previously documented in women with this condition.

This study reported that CYP21A2 heterozygous mutations do not significantly contribute to the pathogenesis of polycystic ovary syndrome.

In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.

This study found that cyproterone acetate significantly reduced both serum 3α-AdiolG levels and hirsutism scores in women with idiopathic hirsutism, PCOS, or 21-hydroxylase deficiency, suggesting its effectiveness in treating excessive hair growth.

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

In this study, cyproterone acetate was found to be effective in treating 'idiopathic' hirsutism, while a combination of ethinyloestradiol and lynoestrenol reduced hair growth in fewer patients despite uniformly lowering testosterone levels.